1
|
Chen L, Wang YH, Cheng YQ, Du MZ, Shi J,
Fan XS, Zhou XL, Zhang YF, Guo LC, Xu GF, et al: Risk factors of
lymph node metastasis in 1620 early gastric carcinoma radical
resections in Jiangsu Province in China: A multicenter
clinicopathological study. J Dig Dis. 18:556–565. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Hoteya S, Matsui A, Iizuka T, Kikuchi D,
Yamada A, Yamashita S, Furuhata T, Domon K, Nakamura M, Mitani T,
et al: Comparison of the clinicopathological characteristics and
results of endoscopic submucosal dissection for esophagogastric
junction and non-junctional cancers. Digestion. 87:29–33. 2013.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Tate DJ, Klein A, Sidhu M, Desomer L,
Awadie H, Lee EYT, Mahajan H, McLeod D and Bourke MJ: Endoscopic
submucosal dissection for suspected early gastric cancer: Absolute
versus expanded criteria in a large Western cohort (with video).
Gastrointest Endosc. 90:467–479.e4. 2019. View Article : Google Scholar : PubMed/NCBI
|
4
|
Yang J, Li J, Deng Q, Chen Z, He K, Chen Y
and Fu Z: Effect of neoadjuvant chemotherapy combined with arterial
chemoembolization on short-term clinical outcome of locally
advanced gastric cancer. BMC Cancer. 23:2462023. View Article : Google Scholar : PubMed/NCBI
|
5
|
Wang S, Yin M, Ma Y, Li X, Jin S, Liu T,
Zhu M, Liu C and Wu G: Transcatheter arterial chemoembolization
with lipiodol for advanced gastric fundus and cardia cancer. Eur J
Cancer Prev. 32:305–306. 2023. View Article : Google Scholar : PubMed/NCBI
|
6
|
Peng D, Zhang B, Yuan C, Tong Y and Zhang
W: Gastric transcatheter chemoembolization can resolve advanced
gastric cancer presenting with obstruction. Front Surg.
9:10040642022. View Article : Google Scholar : PubMed/NCBI
|
7
|
Sunde B, Ericson J, Kumagai K, Lundell L,
Tsai JA, Lindblad M, Rouvelas I, Friesland S, Wang N and Nilsson M:
Relief of dysphagia during neoadjuvant treatment for cancer of the
esophagus or gastroesophageal junction. Dis Esophagus. 29:442–447.
2016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Cools-Lartigue J, Jones D, Spicer J,
Zourikian T, Rousseau M, Eckert E, Alcindor T, Vanhuyse M, Asselah
J and Ferri LE: Management of dysphagia in esophageal
adenocarcinoma patients undergoing neoadjuvant chemotherapy: Can
invasive tube feeding be avoided? Ann Surg Oncol. 22:1858–1865.
2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Arnold M, Moore SP, Hassler S,
Ellison-Loschmann L, Forman D and Bray F: The burden of stomach
cancer in indigenous populations: A systematic review and global
assessment. Gut. 63:64–71. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Li N, Wang G, Duan G, Li Z, Zheng Y, Wang
Z and Li G: Clinical observation of transcatheter arterial
chemoembolization in super-aged patients with advanced gastric
cancer. Support Care Cancer. 30:1441–1450. 2022. View Article : Google Scholar : PubMed/NCBI
|
11
|
Siddiqui AA, Sarkar A, Beltz S, Lewis J,
Loren D, Kowalski T, Fang J, Hilden K and Adler DG: Placement of
fully covered self-expandable metal stents in patients with locally
advanced esophageal cancer before neoadjuvant therapy. Gastrointest
Endosc. 76:44–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Di Fiore F, Lecleire S, Pop D, Rigal O,
Hamidou H, Paillot B, Ducrotté P, Lerebours E and Michel P:
Baseline nutritional status is predictive of response to treatment
and survival in patients treated by definitive chemoradiotherapy
for a locally advanced esophageal cancer. Am J Gastroenterol.
102:2557–2563. 2007. View Article : Google Scholar : PubMed/NCBI
|
13
|
Lagergren J and Lagergren P: Recent
developments in esophageal adenocarcinoma. CA Cancer J Clin.
63:232–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Nagaraja V, Cox MR and Eslick GD: Safety
and efficacy of esophageal stents preceding or during neoadjuvant
chemotherapy for esophageal cancer: A systematic review and
meta-analysis. J Gastrointest Oncol. 5:119–126. 2014.PubMed/NCBI
|
15
|
Tey J, Soon YY, Koh WY, Leong CN, Choo BA,
Ho F, Vellayappan B, Lim K and Tham IW: Palliative radiotherapy for
gastric cancer: A systematic review and meta-analysis. Oncotarget.
8:25797–25805. 2017. View Article : Google Scholar : PubMed/NCBI
|
16
|
Kato H, Tsutsumi K and Okada H: Recent
advancements in stent therapy in patients with malignant
gastroduodenal outlet obstruction. Ann Transl Med. 5:1862017.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Hori Y, Naitoh I, Hayashi K, Ban T,
Natsume M, Okumura F, Nakazawa T, Takada H, Hirano A, Jinno N, et
al: Predictors of stent dysfunction after self-expandable metal
stent placement for malignant gastric outlet obstruction: tumor
ingrowth in uncovered stents and migration of covered stents. Surg
Endosc. 31:4165–4173. 2017. View Article : Google Scholar : PubMed/NCBI
|
18
|
Mariette C, Gronnier C, Duhamel A, Mabrut
JY, Bail JP, Carrere N, Lefevre JH, Meunier B, Collet D, Piessen G,
et al: Self-expanding covered metallic stent as a bridge to surgery
in esophageal cancer: Impact on oncologic outcomes. J Am Coll Surg.
220:287–296. 2015. View Article : Google Scholar : PubMed/NCBI
|
19
|
Lee H, Min BH, Lee JH, Shin CM, Kim Y,
Chung H and Lee SH: Covered metallic stents with an anti-migration
design vs. uncovered stents for the palliation of malignant gastric
outlet obstruction: A multicenter, randomized trial. Am J
Gastroenterol. 110:1440–1449. 2015. View Article : Google Scholar : PubMed/NCBI
|
20
|
Sinapi I, Navez B, Hamoir M, Schmitz S,
Machiels JP, Deprez PH and Van den Eynde M: Seeding of the
percutaneous endoscopic gastrostomy site from head and neck
carcinoma: Case report and review of the literature. Head Neck.
35:E209–E212. 2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Mariette C, De Botton ML and Piessen G:
Surgery in esophageal and gastric cancer patients: What is the role
for nutrition support in your daily practice? Ann Surg Oncol.
19:2128–2134. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Chen L, Shi H, Che Y, Sun W, Niu X and Lu
W: Efficacy of endostatin combined with continuous transcatheter
arterial infusion and chemoembolization on gastric cancer with
liver metastasis and analysis of prognosis. J BUON. 25:1469–1475.
2020.PubMed/NCBI
|
23
|
Wu P and Wang J: Efficacy of
interventional therapy and effect on inflammatory factors in
patients with gastric cancer after chemotherapy. Oncol Lett.
18:1733–1744. 2019.PubMed/NCBI
|
24
|
Wang J, Shi H, Yang G, Han G, Zhao M, Duan
X, Mi L, Han X, Li N, Shi J, et al: Combined intra-arterial and
intravenous chemotherapy for unresectable, advanced gastric cancer
has an improved curative effect compared with intravenous
chemotherapy only. Oncol Lett. 15:5662–5670. 2018.PubMed/NCBI
|
25
|
Huang SF, Chien TH, Fang WL, Wang F, Tsai
CY, Hsu JT, Yeh CN, Chen TC, Wu RC, Chiu CT and Yeh TS: The 8th
edition American Joint Committee on gastric cancer pathological
staging classification performs well in a population with high
proportion of locally advanced disease. Eur J Surg Oncol.
44:1634–1639. 2018. View Article : Google Scholar : PubMed/NCBI
|
26
|
Ogilvie AL, Dronfield MW, Ferguson R and
Atkinson M: Palliative intubation of oesophagogastric neoplasms at
fibreoptic endoscopy. Gut. 23:1060–1067. 1982. View Article : Google Scholar : PubMed/NCBI
|
27
|
Xu RH, Wang ZQ, Shen L, Wang W, Lu JW, Dai
G, Xu JM, Zhang YQ, Chen XB, Deng YH, et al: S-1 plus oxaliplatin
versus S-1 plus cisplatin as first-line treatment for advanced
diffuse-type or mixed-type gastric/gastroesophageal junction
adenocarcinoma: A randomized, phase 3 trial. J Clinical Oncol.
37:40172019. View Article : Google Scholar
|
28
|
Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li
FH, Zhou ZW and Chen XQ: Phase II trial of XELOX as first-line
treatment for patients with advanced gastric cancer. Chemotherapy.
56:94–100. 2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
Hawkes E, Okines AF, Papamichael D, Rao S,
Ashley S, Charalambous H, Koukouma A, Chau I and Cunningham D:
Docetaxel and irinotecan as second-line therapy for advanced
oesophagogastric cancer. Eur J Cancer. 47:1146–1151. 2011.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Hironaka S, Ueda S, Yasui H, Nishina T,
Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki
T, et al: Randomized, open-label, phase III study comparing
irinotecan with paclitaxel in patients with advanced gastric cancer
without severe peritoneal metastasis after failure of prior
combination chemotherapy using fluoropyrimidine plus platinum: WJOG
4007 trial. J Clin Oncol. 31:4438–4444. 2013. View Article : Google Scholar : PubMed/NCBI
|
31
|
Gabrielson DK, Scaffidi D, Leung E,
Stoyanoff L, Robinson J, Nisenbaum R, Brezden-Masley C and Darling
PB: Use of an abridged scored Patient-Generated Subjective Global
Assessment (abPG-SGA) as a nutritional screening tool for cancer
patients in an outpatient setting. Nutr Cancer. 65:234–239. 2013.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Yanez B, Pearman T, Lis CG, Beaumont JL
and Cella D: The FACT-G7: A rapid version of the functional
assessment of cancer therapy-general (FACT-G) for monitoring
symptoms and concerns in oncology practice and research. Ann Oncol.
24:1073–1078. 2013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Chiu L, Chiu N, Chow E, Cella D, Beaumont
JL, Lam H, Popovic M, Bedard G, Poon M, Wong E, et al: Comparison
of three shortened questionnaires for assessment of quality of life
in advanced cancer. J Palliat Med. 17:918–923. 2014. View Article : Google Scholar : PubMed/NCBI
|
34
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: Using the common terminology criteria
for adverse events (CTCAE-Version 5.0) to evaluate the severity of
adverse events of anticancer therapies. Actas Dermosifiliogr (Engl
Ed). 112:90–92. 2021. View Article : Google Scholar : PubMed/NCBI
|
35
|
Nishino M, Jagannathan JP, Ramaiya NH and
Van den Abbeele AD: Revised RECIST guideline version 1.1: What
oncologists want to know and what radiologists need to know. AJR Am
J Roentgenol. 195:281–289. 2010. View Article : Google Scholar : PubMed/NCBI
|
36
|
Zhao QY, Luo JC, Su Y, Zhang YJ, Tu GW and
Luo Z: Propensity score matching with R: conventional methods and
new features. Ann Transl Med. 9:8122021. View Article : Google Scholar : PubMed/NCBI
|
37
|
Li M, Zhang J, Wang D, Zhong B, Tucker S,
Lu C, Cheng J, Cao C, Xu J, Xu J and Pan H: A phase II study of
intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and
mitomycin C for advanced nonresectable gastric cancer. Anticancer
Drugs. 20:941–945. 2009. View Article : Google Scholar : PubMed/NCBI
|
38
|
Zhang CW, Zou SC, Shi D and Zhao DJ:
Clinical significance of preoperative regional intra-arterial
infusion chemotherapy for advanced gastric cancer. World J
Gastroenterol. 10:3070–3072. 2004. View Article : Google Scholar : PubMed/NCBI
|
39
|
Fu Y, Weiss CR, Paudel K, Shin EJ,
Kedziorek D, Arepally A, Anders RA and Kraitchman DL: Bariatric
arterial embolization: Effect of microsphere size on the
suppression of fundal ghrelin expression and weight change in a
swine model. Radiology. 289:83–89. 2018. View Article : Google Scholar : PubMed/NCBI
|
40
|
Bai ZB, Qin YL, Deng G, Zhao GF, Zhong BY
and Teng GJ: Bariatric embolization of the left gastric arteries
for the treatment of obesity: 9-Month data in 5 patients. Obes
Surg. 28:907–915. 2018. View Article : Google Scholar : PubMed/NCBI
|
41
|
Weiss CR, Akinwande O, Paudel K, Cheskin
LJ, Holly B, Hong K, Fischman AM, Patel RS, Shin EJ, Steele KE, et
al: Clinical safety of bariatric arterial embolization: Preliminary
results of the BEAT obesity trial. Radiology. 283:598–608. 2017.
View Article : Google Scholar : PubMed/NCBI
|